NTLA-2002 Gene Therapy Safely Prevents HAE Attacks: Trial Data
A single infusion of the investigational gene therapy NTLA-2002 was well tolerated at two different doses and reduced the number of swelling attacks in people with hereditary angioedema (HAE) by more than 90%, according to interim results from the Phase 1 portion of a Phase 1/2 trial. The…